Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib
To the Editor: TAp63a is the predominant member of the Trp53 family (consisting of the tumor suppressors Trp53, Trp63 and Trp73), expressed in primordial follicle oocytes 1 and is essential for oocyte death after genotoxic stress 2 . How DNA damage leads to the activation of TAp63a is poorly defined. Gonfloni et al. 3 reported that inhibition of c-Abl with imatinib (Gleevec), which was designed to inhibit the oncogenic kinase BCR-ABL, protects oocytes from cisplatin-induced killing in mice, and therefore they proposed that c-Abl is crucial for the induction of TAp63-mediated apoptosis. However, the relationships between c-ABL, TAp63 and DNA damage-induced cell death are complex 4, 5 , and imatinib itself is actually known to promote apoptosis by inhibiting certain kinases that promote cell survival, such as the stem cell factor receptor, c-Kit 6, 7 . Accordingly, imatinib is used clinically for the treatment of not only BCR-ABL + chronic myelogenous leukemia but also c-Kit-mutated gastrointestinal stromal tumors 8 . Of particular concern, c-Kit is crucial for oocyte survival, with blocking antibodies to c-Kit causing follicular atresia 9 . We therefore independently explored the impact of imatinib on the response of oocytes to DNA damage induced by cisplatin. We found that imatinib did not protect primordial follicle oocytes from cisplatin-induced apoptosis or prevent loss of fertility in two independent strains of mice.
For in vivo analysis, we treated CD1 mice (the same strain of wildtype mice used by Gonfloni et al. 3 ) at postnatal day 7 (P7) with vehicle (PBS) or imatinib (7.5 mg per kg body weight intraperitoneally (i.p.)) or cisplatin (5 mg per kg body weight i.p.), or both imatinib and cisplatin administered together (as was done by Gonfloni et al. 3 ). We collected ovaries at P10 and quantified ovarian follicles using established methodology 10, 11 (Fig. 1a,b and Supplementary Table 1 and Supplementary Methods). In contrast to the data reported by Gonfloni et al. 3 , coadministration of imatinib did not rescue primordial follicles from elimination caused by exposure to cisplatin. As Gonfloni et al. 3 did not report the primordial follicle count per se (rather, they reported on the composite of the primordial follicle count plus the larger primary follicle count), how they defined primordial follicles in their study is unclear.
We also performed a similar analysis with a second wild-type mouse strain (C57BL/6), with imatinib or vehicle administered 2 h before cisplatin or vehicle. As with the CD1 strain, we observed no rescue of cisplatin-induced oocyte death in the C57BL/6 strain ( Supplementary  Fig. 1a,b and Supplementary Table 1) . In our studies, treatment with imatinib alone increased by nearly fivefold the numbers of pyknotic bodies (oocytes with nuclear fragmentation, a hallmark of apoptosis) observed in ovaries in vivo (at P10, P < 0.03). This is consistent with in vivo proapoptotic activity of imatinib in oocytes ( Supplementary  Fig. 1c ) and the notion that an imatinib-sensitive kinase, most likely c-Kit, is crucial for the survival of female germ cells 12 .
Notably, TUNEL staining confirmed that pretreatment with imatinib did not cause a reduction in the number of apoptotic cells in ovaries of mice exposed to cisplatin for 24 or 48 h ( Supplementary  Fig. 2 ). When we analyzed mice treated at P5 or P7 as adults at P49 (Supplementary Table 2 ) or at 9-11 months of age (Supplementary Table 3 ), we observed no protection against oocyte killing after treatment with imatinib before injection of cisplatin, compared to treatment with cisplatin alone. We observed similar depletion of primordial follicles in both cisplatin-and imatinib plus cisplatin-treated ovaries at P49 (P < 0.05 both, for cisplatin-treated versus vehicle-treated ovaries and for imatinib plus cisplatin-versus vehicle-treated ovaries; Supplementary Fig. 3 ). We observed no significant differences in depletion of primary or secondary follicles after treatment with imatinib plus cisplatin versus cisplatin alone (P = 0.08 for both primary and secondary follicles). Representative histologic sections are shown in Supplementary Figure 4a ,b (P49 and 9-11 months, respectively). We also performed in vitro analysis, with imatinib (10 mM) or vehicle added to whole P5 C57BL/6 ovary cultures for 2 h followed by exposure to cisplatin (20 mM) or vehicle. After a further 24-48 h in culture, quantification of follicles (which contain oocytes) and TUNEL staining demonstrated no protection afforded by imatinib ( Supplementary  Figs. 5a ,b and 6 and Supplementary Table 4) .
To study cisplatin-induced infertility, mice that had been treated at P7 with vehicle, imatinib (7.5 mg per kg body weight i.p.), cisplatin (5 mg per kg body weight i.p.) or both imatinib and cisplatin administered together were studied in mating rounds of approximately 5 weeks, as described in Gonfloni et al. 3 from the age of 6 weeks (Supplementary Table 5 ). We calculated the proportion of pregnant mothers and the average pup number per mating round for the CD1 strain. We observed no difference for the co-administration of imatinib with cisplatin compared with cisplatin alone (Fig. 1c,d ). The total number of pups as per Gonfloni et al. 3 was no different for mice treated with imatinib and cisplatin versus those treated with cisplatin alone ( Fig. 1e and Supplementary Table 5) .
In their breeding studies, Gonfloni et al. 3 did not provide a statistical analysis in support of their assertion that imatinib preserved fertility of mice exposed to cisplatin. The most stringent measure of reproductive potential is provided by analysis of fertility (the ability to produce a litter within 12 weeks of mating). To study infertility, rather than just the proportion of mice becoming pregnant within the short 5-week mating rounds described by Gonfloni et al. 3 , we observed breeders for a total of 12 weeks after previous mating or delivery. Histologic analysis of ovaries from adult females that became sterile during these breeding studies (Supplementary Table 6 ) confirmed the absence of viable ovarian follicles (Supplementary Fig. 4c ). The proportion of females in each treatment group noted to be fertile at each round of npg co r r e s p o n d e n c e nature medicine volume 18 | number 8 | august 2012potential effects of imatinib on oocytes and female fertility. Thus, we find no support for "a new use for imatinib, aimed at preserving oocytes of the follicle reserve during chemotherapeutic treatments" 3 and urge caution in this regard.
breeding and the average number of pups per litter (once the mother became pregnant) were determined. Ovulatory follicles present beyond 6 weeks after treatment were considered to be derived from primordial follicles that survived cisplatin treatment, which indeed is not sterilizing until after three rounds of breeding 3 . In our studies, after allowing female breeders to continue mating for a total of 12 weeks after previous delivery (or until they became pregnant, whichever occurred first, either of these being considerably longer than the 1 week of mating time observed by Gonfloni et al. 3 ), we observed that treatment with cisplatin at P5-P7 caused a significant deficit in fertility (P = 0.02 PBS versus cisplatin), with only 72% of females remaining fertile by breeding round 6 compared with 100% in the vehicle-treated group. Of note, in up to six rounds of breeding, we found no evidence for rescue of cisplatin-induced loss of fertility by pretreatment with imatinib ( Supplementary Fig. 6a and Supplementary Table 6 ). The likelihood of infertility in each treatment group was no different between females treated with imatinib before cisplatin and those treated with cisplatin alone (P > 0.3 for imatinib before cisplatin versus cisplatin alone, Kaplan-Meier analysis) (Supplementary Fig. 6b ). Consistent with this, the average pup numbers seen at each breeding round in litters treated with imatinib before cisplatin were not significantly different from those seen in litters from females treated with cisplatin alone (P > 0.6) (Supplementary Fig. 6a ).
In conclusion, we have shown that imatinib does not protect primordial follicle oocytes from cisplatin-induced apoptosis and loss of fertility in two independent strains of mice. These results indicate that imatinib-sensitive kinases, such as c-Abl, are not required for the DNA damage-activated oocyte apoptosis that is mediated by TAp63. Indeed, the imatinib-sensitive kinase c-Kit is known to be crucial for the survival of female germ cells 9 , heightening concerns about the Figure 1 Pretreatment with imatinib does not protect primordial follicle oocytes from DNA damage-induced death or rescue cisplatin-induced loss of fertility in CD1 mice. P5 CD1 female pups were treated with vehicle (PBS), imatinib (7.5 mg per kg body weight i.p.), cisplatin (5 mg per kg body weight), imatinib and cisplatin administered together, cisplatin administered before imatinib or imatinib administered 2 h before cisplatin. Ovaries were harvested at P10. (a) H&E staining of ovaries: vehicle-treated and imatinib-treated ovaries show numerous primordial follicles with oocytes (green arrows). In all cisplatin treatments or different regimens of imatinib plus cisplatin treatments, oocyte-containing primordial follicles are absent, but empty follicle-like structures lacking an oocyte are numerous (red arrowheads). Scale bar, 50 µm. (b) Quantification of primordial, primary and secondary follicles in CD1 mice treated as above and analyzed at P10. No differences in primary and secondary follicle numbers were observed among groups (not shown). For comparison with untreated controls: **P < 0.01, ***P < 0.001, n = 3 ovaries per treatment group. (c-e) P5 CD1 female pups were treated with vehicle (PBS), or imatinib (7.5 mg per kg body weight i.p.), cisplatin (5 per kg body weight) or imatinib and cisplatin administered together and allowed to mature. Mice commenced breeding trials at P42 with proven wild-type males, and the mating procedure was repeated at regular intervals (about every 5 weeks) as per Gonfloni et al. 3 . (c) The proportion of cisplatin-treated females becoming pregnant (fraction of pregnant mothers as reported in Gonfloni et al. 3 ) was not altered by co-administration of imatinib (Kaplan-Meier analysis, cisplatin versus imatinib plus cisplatin P > 0.7, n = 8-11 mice per treatment group). (d) The average pup number per mating round was not altered by co-administration of imatinib (n = 7-11 pups per breeding round per treatment). (e) The total pup number generated as a result of the breedings described above was not altered by coadministration of imatinib (n = 319, 334, 4 and 5 pups, respectively). kinase receptors such as c-Kit or platelet-derived growth factor 6 . Pretreatment with GNF-2, as we also reported for imatinib 2 , prevented TAp63a accumulation and activation induced by cisplatin in a human Saos-2 p53-null stable cell line expressing TAp63a under the control of a tetracycline-inducible promoter ( Supplementary  Fig. 4) . We observed that GNF-2 can also protect the mouse oocytes from cisplatin-induced death (Fig. 1f,g ).
In this new analysis, we adopted a robust methodology to estimate the loss of perinatal oocytes in a large number of untreated and treated gonads. Follicles were identified exclusively by immunohistochemistry for an antigen specific for germ cells (Msy2) and by the number of layers surrounding the oocyte. This analysis relies on a clear-cut staining procedure that, while facilitating the counting of viable oocytes, at the same time allows inclusion in the counting a higher number of mid-ovary slices for each gonad (approximately ten sections per ovary; we counted one section in every three). We adopted a previously reported procedure 7 that focuses on the population of follicle (primary and primordial) expressing high amounts of TAp63a. Follicle classification and counting considering only two populations is less error prone and is sufficiently informative for the purpose. In addition, within the population of reserve oocytes rescued by the treatment with imatinib, we did not find a predominance of primary follicles versus primordial ones, as also clearly illustrated in Figure 1a ,f and in Supplementary Figure 5 .
Given that Kerr et al. 1 used doses of cisplatin resulting in oocyte degeneration that cannot be rescued by imatinib, it is not surprising that, in the mating experiments, they could not show any preservation of fertility. On the one hand, we accept that a larger number of mice than used in our initial study should be considered before reaching solid conclusions. On the other hand, the number of mice we used was clearly reported in our paper 2 . At the moment, consistent with our report that fertility is prolongued by imatinib in cisplatin-treated mice 2 , we can confirm that, after treatment with appropriate doses of cisplatin, oocytes of the follicle reserve at P42 are much more abundant in ovaries pretreated with GNF-2 (Supplementary Fig. 6 ).
Finally, we show that pharmacological inhibition of c-Abl can have an impact on the DNA damage signaling response at a very early stage. We found that preincubation with either imatinib or GNF-2 prevents H2AX phosphorylation on Ser139 (indicated as g-H2AX), an early marker of the DNA damage response (DDR). We analyzed whole-ovary cultures exposed to either CDDP or bleomycin, a radiomimetic compound, by means of immunofluorescence and western blotting. Notably, bleomycin could induce a massive phosphorylation of H2AX on Ser139 (Fig. 1h-j) within a short time interval. Treatment with either c-Abl inhibitor resulted in a drastic reduction of Ser139 phosphorylation in H2AX. As a control, we also tested a potent inhibitor (Ku55933) of ATM, a PI3K-related kinase mainly involved in Ser139 phosphorylation of H2AX following DNA damage. The effect of Ku55933 mirrored those obtained with both c-Abl inhibitors (Fig. 1j) .
Recent evidence supports a role of c-Abl in the early stage of the DDR 8, 9 . Several studies have placed H2AX post-translational modifications at the center stage of DDR paths. These modifications are
Maiani et al. reply:
Kerr et al. 1 report that imatinib does not protect primordial oocytes from cisplatin-induced apoptosis. This stands in contrast with the results of a recent report from our group in Nature Medicine 2 . Furthermore, Kerr et al. 1 claim that imatinib causes oocyte death, possibly by blocking the tyrosine kinase activity of the stem cell factor receptor c-Kit, which is considered crucial for oocyte survival 3 . They state that they find no support for a new use for imatinib aimed at preserving the follicle reserve during cancer therapy.
While attempting to reconcile the contradictory outcomes of their study and ours, we noticed that Kerr et al. 1 used a hospital-grade cisplatin solution (cisplatin-HG) commonly used in cancer therapy. In comparing the effects on cell line and oocyte survival of cisplatin-HG and Sigma cisplatin (which we used in our original report 2 ), we observed that the latter is consistently less effective in inducing cell death if compared to apparently equivalent solutions of cisplatin-HG (Teva, 1 mg ml -1 ) (Supplementary Fig. 1 ). This may be due to the low solubility of Sigma cisplatin in PBS at concentrations around 1 mg ml -1 .
Therefore, we repeated some crucial experiments using cisplatin-HG at a dose (2.5 mg per kg body weight) that, according to the titration curve (Supplementary Fig. 1c) , induces the same effect caused by 5.0 mg per kg body weight of Sigma cisplatin, the concentration used in our original report. The results of these new experiments confirm that imatinib prevents oocytes of primordial and primary follicles from degeneration induced by cisplatin-HG in vivo (Fig. 1a,b) . We also clearly observed oocyte protection ex vivo, both on ovary fragments cultured in the presence of cisplatin for 24 h (Fig. 1c,d ) and on intact gonads, as evaluated by TUNEL staining (Fig. 1e) . In addition, as in our original report 2 , we did not observe any significant toxic effect on oocytes by imatinib alone either in vivo or ex vivo at a similar range of concentrations (or even higher) to those reported by Kerr et al. 1 (in vivo: 7.5-30 mg per kg body weight Supplementary  Fig. 2 ; ex vivo: 1 mM-10 mM, Fig. 1c-e) . Notably, imatinib used at therapeutic doses, which are higher than those used in our studies, has no impact on folliculogenesis or spermatogenesis in a leukemia mouse model 4 .
The major conclusion of Kerr et al. 1 is that "imatinib-sensitive kinases, such as c-Abl, are not required for the DNA damage-activated oocyte apoptosis that is mediated by TAp63. We disagree with this conclusion. We confirm here that imatinib can protect oocytes challenged by cisplatin in three different experimental settings, as the lack of protection reported by Kerr et al. 1 may be only a consequence of excessive oocyte killing caused by higher doses of cisplatin. For additional independent evidence that c-Abl is involved in oocyte degeneration induced by cisplatin, we also tested the ability of GNF-2, a second c-Abl inhibitor 5 (Supplementary Fig. 3) , to protect primordial and primary oocytes after cisplatin incubation. GNF-2 works by an allosteric mechanism that is completely independent from imatinib. This molecule targets a deep pocket in the kinase domain, a site far from the ATP-binding site, only when c-Abl is in the auto-inhibited state. GNF-2 has no affinity for tyrosine npg
